<DOC>
	<DOCNO>NCT00644241</DOCNO>
	<brief_summary>India `` Diabetes Capital World '' 41 million Indians diabetes i.e . every fifth diabetic world Indian1 . Type 2 Diabetes Mellitus ( T2DM ) constitute major chunk diabetes insulin resistance hallmark feature pathogenesis . However , progression disease insulin resistance become stable whereas β - cell function show gradual decline due ongoing apoptosis2 . This ultimately lead inability β - cell cope increase demand insulin cause due insulin resistance manifest hyperglycemia . As β - cell failure progressive inexorable , demonstrate United Kingdom Prospective Diabetes Study3 , patient T2DM would eventually require insulin would difficult achieve attain strict glycemic control . It well know diabetes related complication account morbidity mortality disease prevent delayed strict glycemic control . However , even intensive insulin therapy show glycemic control never perfect patient exhibit hyperglycemia hypoglycemia 24 hour glucose profile4 . Also insulin therapy physiological hepatic `` first - pas '' metabolism insulin require halt hepatic glucose output , responsible fast hyperglycemia5 . This lead researcher evolve various strategy β - cell replacement therapy e.g . pancreatic transplantation islet cell transplantation . Initially result islet cell transplantation dismal induction glucocorticoid free immunosuppressive therapy use adequate number islet cell multiple donor , result islet cell transplantation better6 . However , islet cell transplantation limitation viz insufficient supply , technically demand requirement lifelong immunosuppressive therapy recipient . These shortcoming overcome use stem cell inexhaustible source β -cells . Stem cell primitive cell capable differentiating mature cell body various lineage . Stem cell obtain various source like blastocyst ( embryonal stem cell ) , umbilical cord bone marrow . There evidence suggest stem cell transplantation lead improvement pancreatic endocrine function improvement glycemic control diabetic mice7,8,9,10 various mechanism transdifferentiation regeneration endothelial cell damage islet turn lead regeneration islet cell paracrine action11 . However , till date study demonstrate stem cell therapy effective patient T2DM glycemic control . The investigator propose carry autologous bone marrow - derived stem cell transplantation ( ABMSCT ) patient T2DM , obtain bone marrow superselective injection gastroduodenal artery purification without immunosuppressive regimen . Aim : The aim study reverse hyperglycemia insulin dependency ABMSCT patient type 2 diabetes mellitus . Hypothesis : The investigator hypothesize ABMSCT pancreas patient T2DM , age 30 year insulin requirement 0.7 U/ kg body weight/day 50 U / day whichever less , lead abolition reduction insulin requirement equal 50 % patient period 6 month . It assume ABMSCT lead patient regenerate functional β - cell transdifferentiation regeneration endothelial cell turn cause β - cell neogenesis paracrine effect . Objectives : Primary objective : 1 . Abolition reduction insulin requirement &gt; 50 % end 6 month ABMSCT . 2 . To evaluate increment Glucagon stimulate C - peptide response end 6 month ABMSCT , compare baseline value . Secondary objective : 1 . Any reduction requirement insulin dosage . 2 . Improvement HbA1c level compare baseline .</brief_summary>
	<brief_title>Efficacy Of Autologous Bone Marrow Derived Stem Cell Transplantation In Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>1 . Patients type 2 diabetes mellitus 30 less 75 year age . 2 . Insulin requirement 0.7 IU/kg/d 50 IU/d , whichever less . 3 . GAD antibody negative status . 1 . Patients T1DM secondary diabetes . 2 . Patients serum creatinine &gt; 1.5 mg/dl . 3 . Abnormal liver function test ( define value transaminases &gt; 3 time upper value normal serum bilirubin high normal reference value laboratory ) . 4 . History myocardial infarction unstable angina previous 3 month . 5 . History malignancy current malignancy nonmelanomatous skin cancer . 6 . Patients active infection</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>stem cell therapy</keyword>
	<keyword>T2DM</keyword>
	<keyword>Efficacy Of Autologous Bone Marrow Derived Stem Cell Transplantation In Patients With Type 2 Diabetes Mellitus</keyword>
</DOC>